Bangalore-based biotechnology firm, Biocon plans to launch its oral insulin drug by early 2011, and has started talks with a few firms to licence the drug, a top company official said.
"If everything goes well, we hope that the product will enter the Indian market in early 2011," Biocon's chairman and managing director, Kiran Mazumdar Shaw told reporters here.
The company hopes to sign the licensing agreement next year, depending upon the outcome of the final phase of trial and after securing the regulatory approval, Shaw said.
The clinical trial for the oral insulin drug — IN-105 — has now entered its third phase and is being carried out in 15 research and development centres across India, Shaw said.
The new oral insulin drug is a new proprietary insulin, which is feasible to deliver at room temperature, she said.
The company was also planning to launch another drug called anti-CD6 monoclone antibody in the near future to treat rheumatoid arthritis and psoriasis.
Biocon has targeted to achieve a turnover of Rs2,000 crore in FY10 as compared to Rs1,500 crore in the last fiscal, Shaw said.
Comments